LIPELLA PHARMACEUTICALS

Company snapshot

Pharmaceuticals, Clinical-stage, Rare-disease, 505(b)(2), Liposomal-formulations, Urology

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LIPELLA PHARMACEUTICALS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for LIPELLA PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   LP-10 (Liposomal Tacrolimus) — Phase 2

2. May 23, 2026 Clinical update

   LP-08 80mg — Phase 2

3. May 23, 2026 Clinical update

   LP-10 — Phase 2

4. May 23, 2026 Clinical update

   Ferumoxytol — Phase 1

5. Jun 10, 2025 Patent grant

   Systems and methods of detecting interstitial cystitis

View all clinical trial activity →

• What is LIPELLA PHARMACEUTICALS?

  Lipella Pharmaceuticals is a pharma organization headquartered in Pittsburgh, USA. It trades on NYSE under ticker LIPO. Primary therapeutic focus areas include IC - Interstitial Cystitis, Interstitial Cystitis, Hemorrhagic Cystitis, Oral Lichen Planus. NovaPharmaNews links 4 clin

• Is LIPELLA PHARMACEUTICALS publicly traded?

  Yes. LIPELLA PHARMACEUTICALS is listed with ticker LIPO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does LIPELLA PHARMACEUTICALS develop or market?

  We link 3 drug profile(s) where LIPELLA PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lipella-pharmaceuticals-inc#company-drugs.

• What are the latest developments for LIPELLA PHARMACEUTICALS?

  In the last 12 months our linked public records show 4 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does LIPELLA PHARMACEUTICALS focus on?

  LIPELLA PHARMACEUTICALS focuses on IC - Interstitial Cystitis, Interstitial Cystitis, Hemorrhagic Cystitis based on our analysis of their pipeline programs and drug development activities.